Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Baghdad: Clinical Trials & FDA Approval Profile

University of Baghdad (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 1 active protocols (0 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.0%
Median Closed Enrollment vs National (145 pts)43 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Baghdad
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)1 (0)
Completed vs Stopped Early8 / 1 (5.0%)
Median Closed Actual Enrollment43 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the University of Baghdad Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI